Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | NPY1R | P25929 | 1/20 | 0.65 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30390387 | 1.00 | ALDH1A1 (0.66) | ALDH1A1NPY1RNPY5RPOLBLMNA | |
| SCHEMBL10194532 | 0.95 | ALDH1A1 (0.68) | ALDH1A1NPY1RNPY5RPOLBLMNA | |
| SCHEMBL30390015 | 0.89 | ALDH1A1 (0.64) | ALDH1A1NPY1RNPY5RPOLBLMNA | |
| SCHEMBL25759592 | 0.89 | ALDH1A1 (0.64) | ALDH1A1NPY1RNPY5RPOLBLMNA | |
| SCHEMBL3685227 | 0.85 | ALDH1A1 (0.66) | ALDH1A1NPY1RNPY5RPOLBLMNA | |
| SCHEMBL1928807 | 0.85 | CYP1A2 (0.67) | ALDH1A1NPY1RNPY5RPOLBLMNA | |
| SCHEMBL9927436 | 0.84 | ALDH1A1 (0.68) | ALDH1A1NPY1RNPY5RPOLB | |
| Hydrochloric Acid SCHEMBL1846589 | 0.84 | CYP1A2 (0.66) | ALDH1A1NPY1RNPY5RPOLB | |
| SCHEMBL9942078 | 0.84 | NPY1R (0.67) | ALDH1A1NPY1RNPY5RPOLBLMNA | |
| SCHEMBL6791530 | 0.83 | ALDH1A1 (0.68) | ALDH1A1NPY1RNPY5RPOLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | disclosed |
| WO-2021241875-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | 재단법인 대구경북첨단의료산업진흥재단 | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212121-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | SLC6A2, SLC6A3, SLC6A4 | ALDH1A1 1394/4885NPY1R 711/4885NPY5R 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.